Abstract
Vincristine, adriamycin, and dexamethasone (VAD) chemotherapy protocol is first-choice treatment in newly diagnosed multiple myeloma patients in many centers. Sudden hearing loss associated with vincristine therapy is a rarely observed event in the VAD protocol. We describe a 69-year old male patient diagnosed with multiple myeloma 7 months ago who developed sudden bilateral hearing loss related to vincristine therapy. This uncommon adverse effect of vincristine is discussed and the literature reviewed.
MeSH terms
-
Aged
-
Antineoplastic Agents, Phytogenic / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Dexamethasone / adverse effects
-
Dexamethasone / therapeutic use
-
Doxorubicin / adverse effects
-
Doxorubicin / therapeutic use
-
Hearing Loss, Bilateral / chemically induced*
-
Humans
-
Male
-
Multiple Myeloma / drug therapy
-
Vincristine / adverse effects*
-
Vincristine / therapeutic use
Substances
-
Antineoplastic Agents, Phytogenic
-
Vincristine
-
Dexamethasone
-
Doxorubicin